Albumin binding domain (ABD) has been widely used for the modification of therapeutic proteins (Nilsson et al., 1996), and ABD-fused with affibody molecules have demonstrated reduce immunogenicity, which is more important for in vivo tumor imaging and treatment. This evidence concerns the gene ALB and neoplasm.